Skip to main content
Contact
Search
Keyword
Sign in
Specialties
Allergy & Immunology
Autoimmune
Cath Lab Digest
EMSWorld
Endocrinology & Diabetes
EP Lab Digest
First Report Managed Care
Gastroenterology
Infectious Diseases
Journal of Critical Limb Ischemia
Journal of Invasive Cardiology
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Pulmonology
Rheumatology & Arthritis
Surgery
The Dermatologist
Urology
Vascular Disease Management
Wounds
Home
Events
Education
About
Keyword
About
About The Dermatologist
Meet Our Editorial Board
Meet Our Editorial Team
Author Guidelines
Submit Your Manuscript
Get Permissions
Education
Journal
Current Issue
Archives
Supplements
Subscribe
Departments
Allergen Focus
Business Insider
Case Report
Clinical Tips
Cover Story
DermDX
Expert Insights
Features
HSF-Reviewed Content
Masterclasses in Dermatology Forum
NAAF-Reviewed Content
NEA-Reviewed Content
NPF-Approved Content
NRS-Approved Content
Spotlight
Resources
Dermatology Advances
FDA Alerts
How I Treat
Myth Busters: Alopecia Areata
Podcasts
The Derm NP/PA
Q&A
Quizzes
Videos
Topics
Acne
Aesthetics
Atopic Dermatitis
Hidradenitis Suppurativa
Pediatric Dermatology
Psoriasis
Psoriatic Arthritis
Rosacea
Skin Cancer
Skin of Color
Excellence Forums
Acne
Alopecia Areata
Atopic Dermatitis
Prurigo Nodularis
Psoriasis
Skin Cancer
Type 2 Inflammation
Conference Coverage
Masterclasses in Dermatology
Masterclasses in Dermatology Saturday Morning Live
Music City SCALE
ACMS Annual Conference
AAD Annual Meeting
Fall Clinical 2026
Keyword
About
About The Dermatologist
Meet Our Editorial Board
Meet Our Editorial Team
Author Guidelines
Submit Your Manuscript
Get Permissions
Education
Journal
Current Issue
Archives
Supplements
Subscribe
Departments
Allergen Focus
Business Insider
Case Report
Clinical Tips
Cover Story
DermDX
Expert Insights
Features
HSF-Reviewed Content
Masterclasses in Dermatology Forum
NAAF-Reviewed Content
NEA-Reviewed Content
NPF-Approved Content
NRS-Approved Content
Spotlight
Resources
Dermatology Advances
FDA Alerts
How I Treat
Myth Busters: Alopecia Areata
Podcasts
The Derm NP/PA
Q&A
Quizzes
Videos
Topics
Acne
Aesthetics
Atopic Dermatitis
Hidradenitis Suppurativa
Pediatric Dermatology
Psoriasis
Psoriatic Arthritis
Rosacea
Skin Cancer
Skin of Color
Excellence Forums
Acne
Alopecia Areata
Atopic Dermatitis
Prurigo Nodularis
Psoriasis
Skin Cancer
Type 2 Inflammation
Conference Coverage
Masterclasses in Dermatology
Masterclasses in Dermatology Saturday Morning Live
Music City SCALE
ACMS Annual Conference
AAD Annual Meeting
Fall Clinical 2026
Dermatology Advances
Libtayo Shows Promise as Adjuvant Therapy in High-Risk CSCC: Phase 3 C-POST Trial Results
Breaking Ground in Skin Cancer: Phase 3 C-POST Trial Demonstrates Significant Clinical Benefits of Libtayo in High-Risk Cutaneous Squamous Cell Carcinoma
Risankizumab Demonstrates Superiority and Efficacy Overall Among Adult Patients with Moderate Plaque Psoriasis
Risankizumab Achieved Superiority Vs Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis
Upadacitinib Approved For Adults and Children Aged 12 Years and Older With Refractory, Moderate to Severe Atopic Dermatitis
Tildrakizumab Presented Consistent Reduction of Detectable Psoriasis Through 5 Years
Risankizumab: The Only IL-23 Inhibitor FDA-Approved for Adults with Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis
Newer IL-23 Inhibitor Demonstrates Improvement in Nail, Scalp, and Palmoplantar Psoriasis
Tildrakizumab Shows Sustained Efficacy, Safety Over a 5-Year Period for Moderate to Severe Plaque Psoriasis
Patients Receiving Risankizumab Report Immediate and Sustained Improvements in Severity, HRQL, and Mental Health in Two Phase 3 Clinical Trials
Risankizumab Demonstrates Superiority for Treatment of Adults with Moderate to Severe Plaque Psoriasis in Head-to-head Phase 3 Trial
Dermatology Advances Updates
Videos
Insights on Tildrakizumab: Durability and Safety
07/09/2021
In this video Dr Farberg discusses his insights on tildrakizumab’s durability and safety following his poster presentation at AAD 2021.
In this video Dr Farberg discusses his insights on tildrakizumab’s durability and safety following his poster presentation at AAD 2021.
In this video Dr Farberg...
07/09/2021
The Dermatologist
Videos
Dr Blauvelt on Improvements in Safety in Biologic Therapies
08/13/2020
In the video below, Andrew Blauvelt, MD, MBA, discusses how the thought on safety with biologic use has changed over the years.
In the video below, Andrew Blauvelt, MD, MBA, discusses how the thought on safety with biologic use has changed over the years.
In the video below, Andrew...
08/13/2020
The Dermatologist